<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218634</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-18603-1</org_study_id>
    <secondary_id>R01DA018603</secondary_id>
    <nct_id>NCT00218634</nct_id>
  </id_info>
  <brief_title>Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1</brief_title>
  <official_title>CBT for Depression &amp; Adherence in HIV Methadone Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with HIV, depression, and opioid-dependence are at high risk for poor health
      outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for
      depression and HIV medication adherence in patients with opioid dependence who are receiving
      methadone maintenance treatment. The project is based on our pilot work with close attention
      to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et
      al., 2001).

      Depression is highly comorbid with both HIV infection and with opioid dependence. Depression
      and substance abuse are both associated with poor adherence to antiretroviral medications.
      Patients with HIV, depression, and opioid dependence are at high risk for poor health
      outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious
      psychosocial intervention for depression; and research by the PI and others has shown that
      cognitive-behavioral interventions have been successful in promoting adherence to HIV
      medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Symptoms of depression (i.e. low motivation, poor concentration, loss of interest, sad mood,
      suicidal ideation) that occur in the context of substance abuse or dependence can interfere
      with self-care behaviors necessary for maintaining HIV care, as well as interfere with
      potential benefit from an intervention that focuses on adherence alone. We hypothesize that
      teaching skills to cope with depression will improve the outcome from an adherence
      intervention to promote healthier living with HIV, in HIV+ opioid dependent individuals in
      methadone maintenance treatment.

      Overview of Research Plan. Patients who are HIV positive and who are receiving methadone
      maintenance for opioid dependence will be randomized to treatment with either: (1) CBT, a
      combination of CBT for depression and HIV medication adherence, including a single session
      intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction
      with physician feedback regarding baseline study assessments or (2) the single session
      intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction
      with physician feedback regarding baseline study assessments. Participants will be followed
      for one-year post-randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Medication Adherence at 3-month Follow-up Assessment</measure>
    <time_frame>3-month assessment</time_frame>
    <description>Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Medication Adherence at 12-month Follow-up Assessment</measure>
    <time_frame>12-month follow-up assessment</time_frame>
    <description>Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinician-assessed Depression Rating at 3 Month Follow-up Assessment</measure>
    <time_frame>3 month follow-up</time_frame>
    <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load at 12-month Follow-up Assessment</measure>
    <time_frame>12-month follow-up assessment</time_frame>
    <description>HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Lymphocyte Count at 12-month Follow-up Assessment.</measure>
    <time_frame>12-month follow-up assessment</time_frame>
    <description>CD4+ lymphocyte cell count at 12-month follow-up assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-assessed Depression at 12-month Follow-up Assessment</measure>
    <time_frame>12-month follow-up assessment</time_frame>
    <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load at 3-month Follow-up Assessment</measure>
    <time_frame>3-month assessment</time_frame>
    <description>HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Lymphocyte Count at 3-month Follow-up Assessment.</measure>
    <time_frame>3-month assessment</time_frame>
    <description>CD4+ lymphocyte cell count at 3-month follow-up assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Adherence</condition>
  <condition>Depression</condition>
  <condition>Heroin Dependence</condition>
  <condition>Methadone</condition>
  <condition>Motivational Interviewing</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>CBT-AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive behavioral therapy for adherence and depression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETAU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enhanced treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT-AD</intervention_name>
    <description>Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.</description>
    <arm_group_label>CBT-AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ETAU</intervention_name>
    <description>Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.</description>
    <arm_group_label>ETAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV seropositive

          -  Currently enrolled in methadone maintenance treatment for at least one month

          -  Current major or subsyndromal depression (subsyndromal depression is defined by major
             depression that does not meet full diagnostic criteria but with a clinical global
             impression of severity (CGI-S) of 2 (mildly ill))

          -  Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary
             care provider.

          -  Between the ages of 18 and 65.

        Exclusion Criteria:

          -  Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania),
             or other Axis I psychiatric disorders (other than depression) that would interfere
             with the ability to participate (i.e. CGI-S &gt;6)

          -  Unable or unwilling to provide informed consent.

          -  Currently in cognitive behavioral therapy for depression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Safren, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>January 3, 2012</results_first_submitted>
  <results_first_submitted_qc>June 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2012</results_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven A. Safren</investigator_full_name>
    <investigator_title>Director, Behavioral Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participants from methadone clinics, remainder from MGH or RIH clinics.</recruitment_details>
      <pre_assignment_details>Participants had to screen for study inclusion/exclusion criteria before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CBT-AD</title>
          <description>Cognitive behavioral therapy for adherence and depression</description>
        </group>
        <group group_id="P2">
          <title>ETAU</title>
          <description>Enhanced Treatment as Usual</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBT-AD</title>
          <description>Cognitive behavioral therapy for adherence and depression</description>
        </group>
        <group group_id="B2">
          <title>ETAU</title>
          <description>Enhanced Treatment as Usual</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.05" spread="7.34"/>
                    <measurement group_id="B2" value="46.67" spread="7.05"/>
                    <measurement group_id="B3" value="46.85" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Medication Adherence at 3-month Follow-up Assessment</title>
        <description>Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
        <time_frame>3-month assessment</time_frame>
        <population>We used hierarchical linear modeling (HLM) methods and intent to treat for all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced treatment as usual</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Medication Adherence at 3-month Follow-up Assessment</title>
          <description>Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
          <population>We used hierarchical linear modeling (HLM) methods and intent to treat for all randomized participants.</population>
          <units>percent (doses taken/doses prescribed)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.02" spread="23.23"/>
                    <measurement group_id="O2" value="73.66" spread="25.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We used HLM with weekly visit data for the acute outcome. There were, therefore, 11 time points used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>HLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician-assessed Depression Rating at 3 Month Follow-up Assessment</title>
        <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
        <time_frame>3 month follow-up</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy for Adherence and Depression</title>
            <description>Cognitive behavioral therapy focusing on treating depression and adherence to medication (CBT-AD).</description>
          </group>
          <group group_id="O2">
            <title>Enhanced Treatment as Usual</title>
            <description>Enhanced treatment as usual (ETAU).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-assessed Depression Rating at 3 Month Follow-up Assessment</title>
          <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" spread="10.62"/>
                    <measurement group_id="O2" value="22.7" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>GLM - CBT-AD would be superior to ETAU at post. HLM - CBT-AD would be superior to CBT-AD at follow ups.</p_value_desc>
            <method>GLM and HLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load at 12-month Follow-up Assessment</title>
        <description>HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.</description>
        <time_frame>12-month follow-up assessment</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced treatment as usual</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load at 12-month Follow-up Assessment</title>
          <description>HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>log10 copies/mL</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.203" spread="0.687"/>
                    <measurement group_id="O2" value="2.177" spread="0.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Lymphocyte Count at 12-month Follow-up Assessment.</title>
        <description>CD4+ lymphocyte cell count at 12-month follow-up assessment.</description>
        <time_frame>12-month follow-up assessment</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced treatment as usual</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Lymphocyte Count at 12-month Follow-up Assessment.</title>
          <description>CD4+ lymphocyte cell count at 12-month follow-up assessment.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.94" spread="235.00"/>
                    <measurement group_id="O2" value="502.33" spread="314.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>follow up analysis revealed that CD4, over time, significantly improved over control when covarying out baseline levels.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <p_value_desc>CD4 would be more improved in the treatment condition</p_value_desc>
            <method>HLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Medication Adherence at 12-month Follow-up Assessment</title>
        <description>Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
        <time_frame>12-month follow-up assessment</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced Treatment as Usual</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Medication Adherence at 12-month Follow-up Assessment</title>
          <description>Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>percent (doses taken/doses prescribed)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.49" spread="31.34"/>
                    <measurement group_id="O2" value="61.11" spread="34.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician-assessed Depression at 12-month Follow-up Assessment</title>
        <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
        <time_frame>12-month follow-up assessment</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced Treatment as Usual</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-assessed Depression at 12-month Follow-up Assessment</title>
          <description>Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="9.22"/>
                    <measurement group_id="O2" value="20.00" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load at 3-month Follow-up Assessment</title>
        <description>HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.</description>
        <time_frame>3-month assessment</time_frame>
        <population>We used intent to treat for all data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced Treatment as Usual</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load at 3-month Follow-up Assessment</title>
          <description>HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.</description>
          <population>We used intent to treat for all data analysis.</population>
          <units>log10 copies/mL&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.349" spread="0.928"/>
                    <measurement group_id="O2" value="2.044" spread="0.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Lymphocyte Count at 3-month Follow-up Assessment.</title>
        <description>CD4+ lymphocyte cell count at 3-month follow-up assessment.</description>
        <time_frame>3-month assessment</time_frame>
        <population>We used intent to treat for all analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CBT-AD</title>
            <description>Cognitive behavioral therapy for adherence and depression</description>
          </group>
          <group group_id="O2">
            <title>ETAU</title>
            <description>Enhanced Treatment as Usual</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Lymphocyte Count at 3-month Follow-up Assessment.</title>
          <description>CD4+ lymphocyte cell count at 3-month follow-up assessment.</description>
          <population>We used intent to treat for all analysis.</population>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.97" spread="266.62"/>
                    <measurement group_id="O2" value="539.29" spread="293.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported for a given participant for the time that participant was enrolled in the trial (roughly 1 year).</time_frame>
      <desc>Serious adverse events reported include those that were study related.</desc>
      <group_list>
        <group group_id="E1">
          <title>CBT-AD</title>
          <description>Cognitive behavioral therapy for adherence and depression</description>
        </group>
        <group group_id="E2">
          <title>ETAU</title>
          <description>Enhanced Treatment as Usual</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Safren</name_or_title>
      <organization>Mass General Hospital</organization>
      <phone>617 724 0817</phone>
      <email>ssafren@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

